HomeGNLX • NASDAQ
add
Genelux Corp
Previous close
$3.48
Day range
$3.39 - $3.83
Year range
$3.06 - $40.98
Market cap
101.82M USD
Avg Volume
127.91K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | 0.00 | -100.00% |
Operating expense | 7.00M | 121.41% |
Net income | -6.77M | -93.62% |
Net profit margin | — | — |
Earnings per share | -0.25 | — |
EBITDA | -6.91M | -133.63% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 23.19M | 5,741.56% |
Total assets | 27.89M | 404.30% |
Total liabilities | 8.42M | -79.62% |
Total equity | 19.47M | — |
Shares outstanding | 26.43M | — |
Price to book | 4.70 | — |
Return on assets | -56.49% | — |
Return on capital | -73.05% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -6.77M | -93.62% |
Cash from operations | -6.91M | -355.20% |
Cash from investing | -13.94M | — |
Cash from financing | 401.00K | -26.42% |
Net change in cash | -20.45M | -2,001.85% |
Free cash flow | -4.65M | -7,076.92% |
About
Genelux Corporation is a late clinical-stage public company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Founded
2001
Headquarters
Website
Employees
23
